Consensus Pacific Biosciences of California, Inc.

Stocks

PACB

US69404D1081

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 16:00:00 2026-09-01 EDT			5-day change	1st Jan Change
1.280 ^USD	-5.54%		-15.79%	-31.55%

08-05	Pacific Biosciences of California, Inc., Q2 2026 Earnings Call, Aug 05, 2026
08-05	Pacific Biosciences Announces Restructuring Plan, Cutting 8% of Workforce to Drive Up to $40 Million in Annual Savings by 2027	CI

Evolution of the Average Target: Pacific Biosciences of California, Inc.

Evolution of the Target Price: Pacific Biosciences of California, Inc.

Changes in Analyst Recommendations: Pacific Biosciences of California, Inc.

3106ddb0649abc0ae.sONQTfh9Akab2UOCnTmOjEiz4u3SgalvEz_5y-3n5us._NcpKMwpQA7wvgz201TC2xmLhbe58cI9RGWOidmh09iJkQp8lhZQP_Oydw~c9b0fe75ef669549c36dc99f446db7e2

Analysts' recommendations: Pacific Biosciences of California, Inc.

25-08-07	PacBio reports smaller-than-expected loss in Q2	RE
25-02-14	UBS Adjusts Price Target on Pacific Biosciences of California to $1.50 From $2, Keeps Neutral Rating	MT
24-11-11	UBS Downgrades Pacific Biosciences of California to Neutral From Buy, Cuts Price Target to $2 From $12	MT
24-06-03	Jefferies & Co Initiates Coverage on Pacific Biosciences of California With Buy Rating, $4 Price Target	MT
24-05-15	Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $4 From $10, Maintains Equal-Weight Rating	MT
24-05-13	Piper Sandler Adjusts Price Target on Pacific Biosciences of California to $2 From $6.50, Maintains Neutral Rating	MT
24-04-22	JPMorgan Downgrades Pacific Biosciences of California to Neutral From Overweight	MT
24-04-18	Scotiabank Adjusts Pacific Biosciences of California's Price Target to $8 From $15, Maintains Sector Outperform Rating	MT
24-04-18	Goldman Sachs Downgrades Pacific Biosciences of California to Neutral From Buy, Adjusts Price Target to $2.50 From $7	MT
24-04-17	TD Cowen Adjusts Price Target on Pacific Biosciences of California to $2.50 From $12, Maintains Buy Rating	MT
24-04-10	Goldman Sachs Cuts Price Target on Pacific Biosciences of California to $7 From $9, Maintains Buy Rating	MT
24-02-16	UBS Trims Pacific Biosciences of California Price Target to $12 From $12.50, Maintains Buy Rating	MT
24-01-02	UBS Lifts Price Target on Pacific Biosciences of California to $12.50 From $10, Keeps Buy Rating	MT
23-12-14	Guggenheim Initiates Pacific Biosciences of California With Neutral Rating	MT
23-11-17	UBS Upgrades Pacific Biosciences of California to Buy From Neutral, Cuts Price Target to $10 From $13	MT
23-11-06	Piper Sandler Trims Price Target on Pacific Biosciences of California to $8 From $9, Maintains Neutral Rating	MT
23-10-31	Cantor Fitzgerald Upgrades Pacific Biosciences of California to Overweight From Neutral, Cuts Price Target to $11 From $14	MT
23-10-24	Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $10 From $13, Maintains Equal-Weight Rating	MT
23-09-29	Barclays Cuts Price Target on Pacific Biosciences of California $9 From $14, Maintains Equalweight Rating	MT
23-09-28	Bernstein Starts Pacific Biosciences of California With Outperform Rating, $11 Price Target	MT
23-08-04	UBS Adjusts Price Target on Pacific Biosciences of California to $13 From $12, Maintains Neutral Rating	MT
23-08-03	Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $13 From $12, Maintains Equalweight Rating	MT
23-06-30	Goldman Sachs Starts Pacific Biosciences of California at Buy With $17 Price Target	MT
23-06-05	Canaccord Genuity Adjusts Price Target on Pacific Biosciences of California to $17 From $14, Maintains Buy Rating	MT
23-05-10	Barclays Initiates Pacific Biosciences of California at Equalweight With $14 Price Target	MT

More recommendations

Other Advanced Medical Equipment & Technology

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	PACIFIC BIOSCIENCES OF CALIFORNIA, INC.					+69.13%
	THERMO FISHER SCIENTIFIC, INC.					+2.32%
	DANAHER CORPORATION					+6.74%
	INTUITIVE SURGICAL, INC.					+26.84%
	BOSTON SCIENTIFIC CORPORATION					+29.79%
	EDWARDS LIFESCIENCES CORPORATION					+11.25%
	SIEMENS HEALTHINEERS AG					+15.37%
	AGILENT TECHNOLOGIES, INC.					+13.57%
	WATERS CORPORATION					+5.99%
	RESMED, INC.					+2.56%
	Average					+18.36%
	Weighted average by Cap.					+11.84%